Adolor initiates testing of pain compound
The phase I study is designed to investigate the safety, tolerability and pharmacokinetics of ADL5859 in healthy volunteers following twice a day dosing for seven days. This study
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.